Great West Life Assurance Co. Can decreased its stake in Cambrex Co. (NYSE:CBM) by 5.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,543 shares of the biotechnology company’s stock after selling 2,399 shares during the period. Great West Life Assurance Co. Can owned 0.14% of Cambrex worth $2,441,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in CBM. Creative Planning raised its position in Cambrex by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 1,093 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Cambrex by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 150 shares in the last quarter. Aperio Group LLC increased its stake in shares of Cambrex by 10.3% in the second quarter. Aperio Group LLC now owns 10,528 shares of the biotechnology company’s stock worth $629,000 after purchasing an additional 986 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of Cambrex by 7.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 9,760 shares of the biotechnology company’s stock worth $583,000 after purchasing an additional 680 shares in the last quarter. Finally, NGAM Advisors L.P. increased its stake in shares of Cambrex by 2.4% in the second quarter. NGAM Advisors L.P. now owns 19,452 shares of the biotechnology company’s stock worth $1,162,000 after purchasing an additional 463 shares in the last quarter.

Several equities analysts have recently weighed in on CBM shares. BidaskClub downgraded shares of Cambrex from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. ValuEngine downgraded shares of Cambrex from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Craig Hallum reiterated a “buy” rating and issued a $60.00 target price (down previously from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. Cambrex has an average rating of “Hold” and an average target price of $62.33.

In related news, CEO Steven M. Klosk sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the transaction, the chief executive officer now owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 2.48% of the stock is currently owned by insiders.

Cambrex Co. (CBM) opened at $48.95 on Friday. The firm has a market cap of $1,635.60, a PE ratio of 15.74, a PEG ratio of 1.12 and a beta of 2.26. Cambrex Co. has a 12 month low of $42.55 and a 12 month high of $62.95.

Cambrex (NYSE:CBM) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.08. The firm had revenue of $112.60 million during the quarter, compared to the consensus estimate of $108.44 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The company’s revenue was up 13.4% on a year-over-year basis. During the same quarter last year, the company earned $0.47 earnings per share. analysts expect that Cambrex Co. will post 2.97 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Great West Life Assurance Co. Can Lowers Holdings in Cambrex Co. (CBM)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/12/15/great-west-life-assurance-co-can-lowers-holdings-in-cambrex-co-cbm.html.

Cambrex Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Stock Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related stocks with our FREE daily email newsletter.